 |
 |
 |
| Volume7, 2003 CD ARTICLES |
| Title (Click for Details) |
Vol/Issue |
Page |
| Compounding for the Effects of Weapons of Mass Destruction |
Vol. 7 No. 1 |
10 |
| Diabetes Mellitus: Pathophysiology and Complications |
Vol. 7 No. 1 |
17 |
| Profile of a Practice: Ward Drug Company Diabetic Shoppe and Prescription Compounding Center |
Vol. 7 No. 1 |
21 |
| Natural or Bioidentical Hormone Replacement: What makes the Difference? An Interview with Christopher B. Cutter, MD. |
Vol. 7 No. 1 |
24 |
| Equine Cushing’s Syndrome |
Vol. 7 No. 1 |
27 |
| Establishing and Standardizing Preferred Pharmacy Practices in a Multioffice Infusion Company, Part 2 |
Vol. 7 No. 1 |
32 |
| Packaging Choices for Compounded Materials |
Vol. 7 No. 1 |
37 |
| Technology Spotlight: Barrier Isolators |
Vol. 7 No. 1 |
42 |
| Determining the Availability of a Commercial Drug |
Vol. 7 No. 1 |
44 |
| Calculations |
Vol. 7 No. 1 |
46 |
| Featured Excipient: Flavor Enhancing Agents |
Vol. 7 No. 1 |
48 |
| Basics of Compounding for Terrorist Attacks, Part 1 |
Vol. 7 No. 1 |
51 |
| Amoxicillin 125-mg/5-mL and 250-mg/5-mL Suspensions |
Vol. 7 No. 1 |
55 |
| Atropine 1-mg Gelatin Troches |
Vol. 7 No. 1 |
56 |
| Atropine Sulfate 0.1% for Inhalation |
Vol. 7 No. 1 |
57 |
| Atropine Sulfate 0.5-mg/mL Injection |
Vol. 7 No. 1 |
58 |
| Gentamicin Sulfate 40-mg/mL Injection |
Vol. 7 No. 1 |
59 |
| Levofloxacin 250-mg/5mL Oral Liquid |
Vol. 7 No. 1 |
60 |
| Ofloxacin 250-mg/5-mL Oral Liquid |
Vol. 7 No. 1 |
60 |
| Potassium Iodide 130-mg Capsules and Potassium Iodide 16-mg/mL Oral Liquid |
Vol. 7 No. 1 |
61 |
| Ribavirin 200-mg Capsules |
Vol. 7 No. 1 |
62 |
| Sodium Hypochlorite Disinfectant Solutions |
Vol. 7 No. 1 |
63 |
| Vancomycin HCl 50-mg/mL Oral Solution |
Vol. 7 No. 1 |
64 |
| Stability of Glycopyrrolate Injection at Ambient Temperature and 4°C in Polypropylene Syringes |
Vol. 7 No. 1 |
65 |
| Stability of Succinylcholine Chloride Injection at Ambient Temperature and 4 Degree C in Polypropylene Syringes |
Vol. 7 No. 1 |
68 |
| Use of Cysteine Hydrochloride Injection to Increase the Solubility of Calcium and Phosphates in FreAmine III-Containing Parenteral Nutrition Solutions |
Vol. 7 No. 1 |
71 |
| Wish You Were Here: Deutsche Apotheken Museum (German Museum of Pharmacy) |
Vol. 7 No. 1 |
78 |
| Postcription: Future Trends in High Technology Pharmaceutical Compounding |
Vol. 7 No. 1 |
80 |
| Book and Literature Reviews |
Vol. 7 No. 2 |
84 |
| Legal & Ethical Issues for Pharmacy Websites |
Vol. 7 No. 2 |
88 |
| Panel Discussion: Prohormones |
Vol. 7 No. 2 |
94 |
| Profile of a Practice: Building a Compounding Pharmacy Practice from the Ground Up: Prescription Compounding Solutions, Medford, Oregon |
Vol. 7 No. 2 |
101 |
| Veterinary Transdermal Medications: A to Z |
Vol. 7 No. 2 |
106 |
| Autoclaves for the Sterilization of Compounded Parenteral Products |
Vol. 7 No. 2 |
114 |
| Barcode System and Computerized Balance Speed Compounding and Enhance Accuracy |
Vol. 7 No. 2 |
118 |
| Technology Spotlight: Electronic Balances with Printer and Draft Shield |
Vol. 7 No. 2 |
120 |
| Accuracy of Small-Volume Containers |
Vol. 7 No. 2 |
124 |
| Autoclave Efficiency Validation |
Vol. 7 No. 2 |
126 |
| Calculations |
Vol. 7 No. 2 |
128 |
| Basics of Compounding for Terrorist Attacks, Part 2 |
Vol. 7 No. 2 |
129 |
| Amoxicillin 250-mg Troches |
Vol. 7 No. 2 |
131 |
| Amoxicillin 125-mg Suppositories |
Vol. 7 No. 2 |
131 |
| Chloramphenicol 250-mg Capsules |
Vol. 7 No. 2 |
131 |
| Chloramphenicol 150-mg/5-mL Suspension |
Vol. 7 No. 2 |
131 |
| Cidofovir Suppositories |
Vol. 7 No. 2 |
131 |
| Ciprofloxacin Oral Suspension |
Vol. 7 No. 2 |
131 |
| Clindamycin HCl 150-mg Capsules |
Vol. 7 No. 2 |
132 |
| Clindamycin Phosphate 150-mg Capsules |
Vol. 7 No. 2 |
132 |
| Clindamycin 10-mg/mL Oral Suspension |
Vol. 7 No. 2 |
132 |
| Doxycycline HCl 100-mg Capsules |
Vol. 7 No. 2 |
132 |
| Erythromycin 200-mg Troches |
Vol. 7 No. 2 |
132 |
| Erythromycin 250-mg Suppositories |
Vol. 7 No. 2 |
132 |
| Penicillin G Potassium 20,000,000-units Injection |
Vol. 7 No. 2 |
132 |
| Penicillin G Potassium 1,000,000-unit Injection |
Vol. 7 No. 2 |
132 |
| Ribavirin 33-mg/mL Injection |
Vol. 7 No. 2 |
132 |
| Rifampin 10-mg/mL Oral Suspension |
Vol. 7 No. 2 |
132 |
| Rifampin 150-mg Capsules |
Vol. 7 No. 2 |
132 |
| Rifampin 3-mg/mL Intravenous Infusion |
Vol. 7 No. 2 |
132 |
| Streptomycin Sulfate 400-mg/mL Injection |
Vol. 7 No. 2 |
132 |
| Tetracycline 125-mg/5-mL Syrup |
Vol. 7 No. 2 |
132 |
| Tetracycline HCl 20-mg/mL Intravenous Injection |
Vol. 7 No. 2 |
132 |
| Tetracycline HCl 250-mg Capsules |
Vol. 7 No. 2 |
132 |
| Tetracycline HCl 250-mg Suppositories |
Vol. 7 No. 2 |
133 |
| Vancomycin HCl 250-mg Capsules |
Vol. 7 No. 2 |
133 |
| Albuterol Sulfate 0.5% Inhalation Solution |
Vol. 7 No. 2 |
133 |
| Dimercaptosuccinic Acid 250-mg Capsules |
Vol. 7 No. 2 |
133 |
| Sodium Thiosulfate-Sodium Nitrate Solution |
Vol. 7 No. 2 |
133 |
| Potassium Iodide Saturated Solution |
Vol. 7 No. 2 |
133 |
| Lorazepam 2-mg Gelatin Troches |
Vol. 7 No. 2 |
134 |
| Lorazepam 2-mg Polyethlene Glycol Troches |
Vol. 7 No. 2 |
134 |
| Oral Liquid Suspending Vehicle |
Vol. 7 No. 2 |
134 |
| Diazepam 5-mg/mL Injection |
Vol. 7 No. 2 |
135 |
| Dimercaprol 100-mg/mL Injection USP |
Vol. 7 No. 2 |
136 |
| Dimercaptopropanesulfonate Sodium 50-mg/mL Injection |
Vol. 7 No. 2 |
137 |
| Lorazepam 2-mg Sublingual Tablets |
Vol. 7 No. 2 |
138 |
| Mafenide Acetate 85 mg/g Cream USP |
Vol. 7 No. 2 |
139 |
| Pralidoxime Chloride 50-mg/mL Injection |
Vol. 7 No. 2 |
140 |
| Silver Sulfadiazine 1% Cream |
Vol. 7 No. 2 |
141 |
| Sodium Bicarbonate 8.4% Injection USP |
Vol. 7 No. 2 |
142 |
| Sodium Nitrite 3% Injection USP |
Vol. 7 No. 2 |
143 |
| Sodium Thiosulfate 25% Injection USP |
Vol. 7 No. 2 |
144 |
| Featured Excipient: Plasticizers |
Vol. 7 No. 2 |
145 |
| Stability of Clindamycin Phosphate in AutoDose Infusion System Bags |
Vol. 7 No. 2 |
149 |
| Chemical Stability of Cefazolin Sodium after Reconstituting in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 7 No. 2 |
152 |
| Quantification of Total Dexamethasone Phosphate Delivery by Iontophoresis |
Vol. 7 No. 2 |
155 |
| PostScription: Sterile Product Admixture Preparation |
Vol. 7 No. 2 |
160 |
| Book & Literature Reviews |
Vol. 7 No. 3 |
164 |
| Five Compounds for Treating Diabetes-Related Conditions |
Vol. 7 No. 3 |
170 |
| Ketamine 10 %, Gabapentin 6%, and Nifedipine 2% in PLO |
Vol. 7 No. 3 |
171 |
| Sildenafil 25-mg Troches |
Vol. 7 No. 3 |
171 |
| Prostaglandin E1/Papaverine HCl/Phentolamine Mesylate Injection |
Vol. 7 No. 3 |
171 |
| Misoprostol 0.0024% and Phenytoin 5% Diabetic Ulcer Cream |
Vol. 7 No. 3 |
171 |
| Nifedipine 100- mg/mL in PLO |
Vol. 7 No. 3 |
171 |
| Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer |
Vol. 7 No. 3 |
176 |
| The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP |
Vol. 7 No. 3 |
180 |
| ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) |
Vol. 7 No. 3 |
183 |
| Ketoprofen 10% in PLO |
Vol. 7 No. 3 |
183 |
| Methimazole 5 mg/0.1 mL in PLO (Vet) |
Vol. 7 No. 3 |
183 |
| Wish You Were Here: The Pearson Museum, Springfield, Illinois |
Vol. 7 No. 3 |
184 |
| Treating Canine Hepatic Disease |
Vol. 7 No. 3 |
188 |
| Incubators |
Vol. 7 No. 3 |
193 |
| Further Clarification of HIPAA Regulations |
Vol. 7 No. 3 |
195 |
| Software for the Compounding Pharmacist: An Update |
Vol. 7 No. 3 |
197 |
| Technology Spotlight: Tube Sealers |
Vol. 7 No. 3 |
206 |
| Accuracy of Graduated Cylinders |
Vol. 7 No. 3 |
208 |
| Calculations |
Vol. 7 No. 3 |
212 |
| Product Containment in the Compounding Laboratory |
Vol. 7 No. 3 |
213 |
| Dexamethasone Phosphate 0.05% Ophthalmic Ointment |
Vol. 7 No. 3 |
215 |
| Dexamethasone Phosphate 0.1% Topical Cream |
Vol. 7 No. 3 |
216 |
| Dimenhydrinate 5-mg/mL Oral Liquid |
Vol. 7 No. 3 |
217 |
| Epinephrine Bitartrate 2% Ophthalmic Solution |
Vol. 7 No. 3 |
218 |
| Ergotamine Tartrate 2-mg Sublingual Tablets |
Vol. 7 No. 3 |
219 |
| Hyoscyamine Sulfate 0.125-mg and Phenobarbital 15-mg/mL Oral Drops |
Vol. 7 No. 3 |
220 |
| Methadone HCl 5-mg/mL Injection |
Vol. 7 No. 3 |
221 |
| Minocycline 10-mg/mL Oral Liquid |
Vol. 7 No. 3 |
222 |
| Phenytoin 6-mg/mL Oral Liquid |
Vol. 7 No. 3 |
223 |
| Tetracycline HCl 2.2-mg/mL Topical Solution |
Vol. 7 No. 3 |
224 |
| Quality-Control Analytical Methods: Principles of pH |
Vol. 7 No. 3 |
225 |
| Standard Operating Procedure: Incubator Temperature Monitoring |
Vol. 7 No. 3 |
228 |
| Stability of Amikacin Sulfate in AutoDose Infusion System Bags |
Vol. 7 No. 3 |
230 |
| Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets |
Vol. 7 No. 3 |
233 |
| PostScription: Too Many Compounders? |
Vol. 7 No. 3 |
240 |
| Book Reviews |
Vol. 7 No. 4 |
244 |
| Literature Review |
Vol. 7 No. 4 |
246 |
| A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 |
Vol. 7 No. 4 |
250 |
| Patient Satisfaction with Pharmacist Intervention and Consultation in HRT |
Vol. 7 No. 4 |
258 |
| Sensitization Therapy for Warts |
Vol. 7 No. 4 |
266 |
| Dinitrochlorobenzene 0.5% to 2.0% in Acetone |
Vol. 7 No. 4 |
270 |
| Dinitrochlorobenzene 0.1% to 1 % in Hydrophilic Petrolatum |
Vol. 7 No. 4 |
270 |
| Diphenylcyclopropenone 0.01% to 0.1% in Acetone |
Vol. 7 No. 4 |
270 |
| Squaric Acid Dibutyl Ester 0.03% to 3.0 in Acetone |
Vol. 7 No. 4 |
270 |
| Cantharidine 0.7% Topical |
Vol. 7 No. 4 |
270 |
| Fluorouracil 5% Gel |
Vol. 7 No. 4 |
270 |
| Podophyllum 25% in Compound Tincture of Benzoin |
Vol. 7 No. 4 |
270 |
| Podophyllum 1% and Salicylic Acid 3% in Flexible Collodion |
Vol. 7 No. 4 |
270 |
| Salicylic Acid 40% Ointment |
Vol. 7 No. 4 |
270 |
| Effectiveness in Oral Rhus toxicodendron Solution for Poison Ivy Prevention |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 2X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 3X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 4X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 5X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 6X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 7X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 8X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 9X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 10X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 11X |
Vol. 7 No. 4 |
272 |
| Rhus Tox Solution 12X |
Vol. 7 No. 4 |
272 |
| Rhus Tox 6X/12X Solution |
Vol. 7 No. 4 |
272 |
| HIPAA Privacy and Security for Providers: The Basics |
Vol. 7 No. 4 |
277 |
| Containment of Hazardous Particulates in the Compounding Pharmacy |
Vol. 7 No. 4 |
281 |
| Technology Spotlight: A USP-Grade Water System |
Vol. 7 No. 4 |
286 |
| Basics of Compounding for Raynaud's Disease |
Vol. 7 No. 4 |
288 |
| Nifedipine in PLO Gel |
Vol. 7 No. 4 |
291 |
| Nitroglycerin 0.2% Ointment |
Vol. 7 No. 4 |
291 |
| Coenzyme Q10 100-mg-in-Oil Capsules |
Vol. 7 No. 4 |
291 |
| Zinc, Magnesium, Caldium and Vitamin D3 Oral Liquid |
Vol. 7 No. 4 |
291 |
| How to Handle a Product Recall |
Vol. 7 No. 4 |
292 |
| Calculations |
Vol. 7 No. 4 |
294 |
| Brompheniramine Maleate 2-mg/5-mL Oral Liquid |
Vol. 7 No. 4 |
295 |
| Chlorpheniramine Maleate 10-mg/mL Injection |
Vol. 7 No. 4 |
296 |
| Chlorpromazine HCl 30-mg/mL Oral Concentrate |
Vol. 7 No. 4 |
297 |
| Desonide 0.05% Otic Liquid |
Vol. 7 No. 4 |
298 |
| Hydroxyprogesterone Caproate 250-mg/mL-in-Oil Injection |
Vol. 7 No. 4 |
299 |
| Meperidine HCl 100-mg/mL and Atropine Sulfate 0.4-mg/mL Injection |
Vol. 7 No. 4 |
300 |
| Meperidine HCl 25-mg/mL and Promethazine HCl 25-mg/mL Injection |
Vol. 7 No. 4 |
301 |
| Methocarbamol 400-mg and Aspirin 325-mg Capsules |
Vol. 7 No. 4 |
302 |
| Perphenazine 4-mg and Amitriptyline HCl 10-mg capsules |
Vol. 7 No. 4 |
303 |
| Triprolidine HCl 1.25-mg/5-mL, Pseudoephedrine HCl 30-mg/5-mL and Codeine Phosphate 10-mg/5-mL Oral Liquid |
Vol. 7 No. 4 |
304 |
| Quality-Control Analytical Methods: Viscosity Measurements |
Vol. 7 No. 4 |
305 |
| Chemical Stability of Cefuroxime Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use |
Vol. 7 No. 4 |
310 |
| Stability of Hydralazine HCl in Both Flavored and Nonflavored Extemporaneous Preparations |
Vol. 7 No. 4 |
313 |
| Postcription: Does Your Pharmacy Practice Follow the Pharmacist Code of Ethics? |
Vol. 7 No. 4 |
320 |
| Book and Literature Reviews |
Vol. 7 No. 5 |
324 |
| A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 |
Vol. 7 No. 5 |
330 |
| Patient Handout - Hormone Replacement Therapy |
Vol. 7 No. 5 |
339 |
| The Role of the Pharmacist in Diabetes Care |
Vol. 7 No. 5 |
341 |
| Understanding Feline Hyperthyroidism |
Vol. 7 No. 5 |
345 |
| Profile of a Practice: Don West, RPh, Lloyd Center Pharmacy, Portland, Oregon |
Vol. 7 No. 5 |
350 |
| Vancomycin Pluronic Gel |
Vol. 7 No. 5 |
354 |
| Sterile Vancomycin Pluronic Gel for Implantation in the Chest-Wall Cavity to Treat Resistant Pneumococcus |
Vol. 7 No. 5 |
354 |
| NDC Numbers: A New Approach |
Vol. 7 No. 5 |
358 |
| Application of USP-NF Standards to Pharmacy Compounding |
Vol. 7 No. 5 |
361 |
| Technology Spotlight: Respiratory Vial Sealers |
Vol. 7 No. 5 |
364 |
| Basics of Compounding for Pediculosis |
Vol. 7 No. 5 |
366 |
| Malathion 0.5% Topical Lotion |
Vol. 7 No. 5 |
368 |
| Ivermectin 1% Crème Rinse |
Vol. 7 No. 5 |
368 |
| Ivermectin 1% Lotion |
Vol. 7 No. 5 |
369 |
| Head Lice Repellant Spray |
Vol. 7 No. 5 |
369 |
| Standard Operating Procedure: Incubator Cleaning |
Vol. 7 No. 5 |
370 |
| Calculations |
Vol. 7 No. 5 |
372 |
| Chloramphenicol 1% Topical Ointment |
Vol. 7 No. 5 |
373 |
| Guanethidine Monosulfate 10-mg and Hydrochlorothiazide 25-mg Capsules |
Vol. 7 No. 5 |
374 |
| Indomethacin 50-mg Suppositories |
Vol. 7 No. 5 |
375 |
| Isoniazid 10-mg/mL Oral Solution |
Vol. 7 No. 5 |
376 |
| Pentazocine HCl 12.5-mg and Aspirin 325-mg Capsules |
Vol. 7 No. 5 |
377 |
| Perphenazine 5-mg/mL Injection |
Vol. 7 No. 5 |
378 |
| Phenylbutazone 100-mg Capsules |
Vol. 7 No. 5 |
379 |
| Reserpine and Hydrochlorothiazide 0.125-mg/25-mg and 0.125-mg/50-mg Capsules |
Vol. 7 No. 5 |
380 |
| Thioridazine HCl 100-mg/mL Concentrated Solution |
Vol. 7 No. 5 |
381 |
| Ursodiol 150-mg Capsules |
Vol. 7 No. 5 |
382 |
| Quality-Control Analytical Methods: Refractometry |
Vol. 7 No. 5 |
383 |
| Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder |
Vol. 7 No. 5 |
386 |
| Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride |
Vol. 7 No. 5 |
389 |
| Educating the Caregiver and Community Pharmacist To Facilitate Provision of Consistent Compounded Medications from the Inpatient to Ambulatory Settings |
Vol. 7 No. 5 |
394 |
| Postcriptions: Compounding Paradox: Taught Less and Practiced More |
Vol. 7 No. 5 |
399 |
| An Ounce of Prevention: Controlling Hazards in Extemporaneous Compounding Practices |
Vol. 7 No. 5 |
401 |
| PreScription: Take Care with Terminology for Altered- and Slow-release Formulations |
Vol. 7 No. 6 |
418 |
| Book & Literature Reviews |
Vol. 7 No. 6 |
420 |
| Sore Nipples in Breastfeeding Mothers: Causes and Treatments |
Vol. 7 No. 6 |
426 |
| Mupirocin 1%, Betamethasone 0.05%, and Miconazole 2% Nipple Ointment |
Vol. 7 No. 6 |
430 |
| Mupirocin 0.5%, Betamethasone 0.025%, Nystatin 25,000-U/g and Clotrimazole 0.25% Nipple Ointment |
Vol. 7 No. 6 |
430 |
| Mupirocin 0.5%, Betamethasone 0.025%, Nystatin 25,000-U/g and Clotrimazole 2.5% Nipple Ointment |
Vol. 7 No. 6 |
430 |
| Compounding for Investigational Studies: The Experience of Ken Hughes, RPh |
Vol. 7 No. 6 |
436 |
| Single-Patient Trials, Extemporaneously Compounded Products and Pharmaceutical Care |
Vol. 7 No. 6 |
441 |
| Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh |
Vol. 7 No. 6 |
449 |
| A Foot in the Door: Marketing Tips |
Vol. 7 No. 6 |
454 |
| Technology Spotlight: Automated Prescription-Dispensing Systems |
Vol. 7 No. 6 |
458 |
| Basics of Compounding for Dry-Skin Conditions |
Vol. 7 No. 6 |
460 |
| Wool Alcohols Ointment |
Vol. 7 No. 6 |
462 |
| Water-Absorbing Ointment |
Vol. 7 No. 6 |
462 |
| Natural Emollient Oil |
Vol. 7 No. 6 |
462 |
| Emulsion Base to be Individualized |
Vol. 7 No. 6 |
462 |
| Premixed Oil Phase for Preparing Oil-in-Water (O/W) Emulsions |
Vol. 7 No. 6 |
463 |
| O/W Emulsion |
Vol. 7 No. 6 |
463 |
| Lotion with Cyclomethicone |
Vol. 7 No. 6 |
463 |
| Water-Repelling Lip-Balm Stick |
Vol. 7 No. 6 |
463 |
| Lip-Balm Stick (Basic Formula for Individualizing) |
Vol. 7 No. 6 |
463 |
| Water-Repelling Lip Ointment |
Vol. 7 No. 6 |
463 |
| Lip Ointment (Basic Ointment for Individualizing) |
Vol. 7 No. 6 |
463 |
| Storage of Bulk Chemicals and Finished Preparations |
Vol. 7 No. 6 |
464 |
| Calculations |
Vol. 7 No. 6 |
466 |
| Bacitracin 500-U/g Ophthalmic Ointment |
Vol. 7 No. 6 |
467 |
| Chloramphenicol 0.5% Ophthalmic Solution |
Vol. 7 No. 6 |
468 |
| Clotrimazole 500-mg Vaginal Suppositories |
Vol. 7 No. 6 |
469 |
| Ergoloid Mesylate 1-mg/mL Oral Liquid |
Vol. 7 No. 6 |
470 |
| Meclocycline Sulfosalicylate 1% Cream |
Vol. 7 No. 6 |
471 |
| Methadone HCl 2.5-mg Capsules |
Vol. 7 No. 6 |
472 |
| Perphenazine 2.5-mg/5-mL Syrup |
Vol. 7 No. 6 |
473 |
| Sulfasalazine 250-mg/5-mL Oral Liquid |
Vol. 7 No. 6 |
474 |
| Tramadol HCl 100-mg Capsules |
Vol. 7 No. 6 |
475 |
| Triprolidine HCl 2.5-mg Capsules |
Vol. 7 No. 6 |
476 |
| Quality-Control Analytical Methods: Specific-Gravity Determinations of Liquids and Semisolids |
Vol. 7 No. 6 |
477 |
| Pharmacokinetics of Sumatriptan 25-mg Oral Tablet Versus 25-mg Extemporaneous Suppository in Healthy Volunteers |
Vol. 7 No. 6 |
481 |
| Stability of Two Concentrations of Tiagabine in an Extemporaneously Compounded Suspension |
Vol. 7 No. 6 |
485 |
| Patient Interest in Pharmacist-Provided Menopause and Hormone Replacement Therapy Consultations |
Vol. 7 No. 6 |
490 |
| PostScription: Changing Pharmacy Regulations Could Affect US Compounders |
Vol. 7 No. 6 |
495 |